UCSF Radiopharmaceutical Facility – FDA 483, Jul 24, 2020
UCSF Radiopharmaceutical Facility in San Francisco, a PET Manufacturer, received a Form 483 with seven observations related to significant deficiencies in quality control, manufacturing processes, and laboratory procedures. Key issues include failure to investigate out-of-specification results, inadequate change control, unvalidated analytical methods, and insufficient stability testing programs. These findings indicate a lack of robust systems to ensure the quality, purity, and identity of their PET drug products.
ID · dc9cd92b-a2f8-4d06-b777-ca7e2d40ce3f
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.